by MASA | Mar 21, 2025 | News, springfield community
🏀 It’s March Madness time! 🏀 This year, Midwest Allergy Sinus Asthma and Respiratory is excited to be part of “Media Madness,” a fun Springfield community initiative organized by Woodward Community Media. Thirty-two local businesses—including us—were randomly matched...
by MASA | Mar 10, 2025 | Immunodeficiency Hypogammaglobulinemia, News, Rare Diseases
Deadline: March 21, 2025 Download CIIC Patient Scholarship Application 2025 : You can submit your application to your provider. CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud...
by MASA | Dec 19, 2024 | Drug Updates
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
by MASA | Dec 15, 2024 | Drug Updates
FDA approved Epinephrine nasal spray (neffy) for emergency treatment of allergic reaction type 1 in August in adults and pediatric patients who weigh at least 30 kg (or around 66 lbs). Neffy provides an option to treat anaphylaxis that does not involve injection,...
by MASA | Aug 15, 2024 | Drug Updates, Patient Resources, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
